Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Orchestra BioMed Holdings, Inc. has granted stock options to 12 newly hired employees, totaling 151,250 shares, as part of its 2025 New Hire Inducement Plan [1][2] - The stock options will vest 25% on the first anniversary of employment, with the remainder vesting quarterly over three years [2] Company Overview - Orchestra BioMed is focused on accelerating high-impact biomedical technologies through partnerships with leading global medical device companies [3] - The company's flagship products include Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and Virtue Sirolimus AngioInfusion™ Balloon (Virtue SAB) for atherosclerotic artery disease, both targeting multi-billion-dollar market opportunities [3] - AVIM Therapy aims to provide significant blood pressure reduction in patients with hypertensive heart disease and has FDA Breakthrough Device Designation [3] - Virtue SAB is a novel drug delivery system for treating coronary ISR, small vessel disease, and below-the-knee peripheral artery disease, also granted Breakthrough Device Designation by the FDA [3]